Published in J Pathol on July 01, 2000
Prostate cancer and inflammation: the evidence. Histopathology (2012) 2.60
Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol (2001) 1.86
Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc Natl Acad Sci U S A (2008) 1.52
Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer (2011) 1.34
Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res (2009) 1.32
Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol (2009) 1.26
aPKClambda/iota promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6. Proc Natl Acad Sci U S A (2009) 1.15
Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol (2003) 1.07
IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol (2011) 1.07
The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways. PLoS One (2009) 1.06
Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Mol Cancer Ther (2009) 1.02
Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol (2011) 1.00
Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer. Prostate Cancer (2013) 0.94
Loss of annexin A1 disrupts normal prostate glandular structure by inducing autocrine IL-6 signaling. Carcinogenesis (2009) 0.94
Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. Am J Pathol (2006) 0.90
Propionibacterium acnes infection induces upregulation of inflammatory genes and cytokine secretion in prostate epithelial cells. BMC Microbiol (2010) 0.89
Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14(+) PD-L1(+) phenotype in prostate cancer. Oncoimmunology (2014) 0.89
Consistent interactions between tumor cell IL-6 and macrophage TNF-α enhance the growth of human prostate cancer cells in the bone of nude mouse. Int Immunopharmacol (2011) 0.89
Proinflammatory cytokine interleukin-6 in prostate carcinogenesis. Am J Clin Exp Urol (2014) 0.87
Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial. Br J Cancer (2014) 0.86
RhoGDIα suppresses growth and survival of prostate cancer cells. Prostate (2011) 0.86
Differential expression and regulation of vitamin D hydroxylases and inflammatory genes in prostate stroma and epithelium by 1,25-dihydroxyvitamin D in men with prostate cancer and an in vitro model. J Steroid Biochem Mol Biol (2014) 0.86
Cellular senescence or EGFR signaling induces Interleukin 6 (IL-6) receptor expression controlled by mammalian target of rapamycin (mTOR). Cell Cycle (2013) 0.84
Il-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migration. BMC Cancer (2015) 0.84
Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation. Mol Cancer Ther (2014) 0.84
Expression of VEGF, EGFR, and IL-6 in gastric adenomas and adenocarcinomas by endoscopic submucosal dissection. Dig Dis Sci (2009) 0.83
Differentially Expressed Genes and Signature Pathways of Human Prostate Cancer. PLoS One (2015) 0.82
Anti-inflammatory and antiproliferative activities of date palm pollen (Phoenix dactylifera) on experimentally-induced atypical prostatic hyperplasia in rats. J Inflamm (Lond) (2011) 0.81
Ligand-independent activation of the androgen receptor in prostate cancer by growth factors and cytokines. J Pathol (2000) 0.81
The profile of prostate epithelial cytokines and its impact on sera prostate specific antigen levels. Inflammation (2009) 0.80
Androgen receptor footprint on the way to prostate cancer progression. World J Urol (2011) 0.80
Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancer. Crit Rev Oncol Hematol (2012) 0.80
IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9. Endocr Relat Cancer (2013) 0.79
A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells. Cancer Immunol Res (2015) 0.78
Immunomodulatory effect of red onion (Allium cepa Linn) scale extract on experimentally induced atypical prostatic hyperplasia in Wistar rats. Mediators Inflamm (2014) 0.77
Benign prostatic hyperplasia complicated with T1DM can be alleviated by treadmill exercise-evidences revealed by the rat model. BMC Urol (2015) 0.76
Co-expression of interleukin-6 and human growth hormone in apparently normal prostate biopsies that ultimately progress to prostate cancer using low pH, high temperature antigen retrieval. J Mol Histol (2006) 0.76
Expression of NF-κB and IL-6 in oral precancerous and cancerous lesions: An immunohistochemical study. Med Oral Patol Oral Cir Bucal (2016) 0.75
Interleukin-30: A novel microenvironmental hallmark of prostate cancer progression. Oncoimmunology (2014) 0.75
Pathogenesis of prostate cancer and hormone refractory prostate cancer. Indian J Urol (2007) 0.75
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res (1994) 3.43
Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus. J Virol (1993) 3.37
Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med (1984) 3.31
Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today (1988) 3.13
The efficacy of dihydrotestosterone transdermal gel before primary hypospadias surgery: a prospective, controlled, randomized study. J Urol (2007) 2.85
Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med (1993) 2.85
Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem (1997) 2.39
Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer (1999) 2.34
Neopterin as a marker for immune system activation. Curr Drug Metab (2002) 2.25
Detection of prostate cancer with a microbubble ultrasound contrast agent. Lancet (2001) 2.23
Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production. J Exp Med (1997) 2.14
Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology (2001) 2.10
Evaluation and management of renal injuries: consensus statement of the renal trauma subcommittee. BJU Int (2004) 2.09
Gastric malt lymphoma with crystalline immunoglobulin inclusions and secondary immunoblastic lymphoma in a cervical lymph node. Pathol Res Pract (1995) 2.09
Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res (1998) 2.07
Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev (2001) 2.03
Immune activation and psoriasis. Lancet (1991) 1.93
Urinary incontinence in the elderly and age-dependent apoptosis of rhabdosphincter cells. Lancet (1999) 1.92
Tetrahydrobiopterin-dependent formation of nitrite and nitrate in murine fibroblasts. J Exp Med (1990) 1.81
Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol (1995) 1.74
Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol (1993) 1.73
Androgen receptors in prostate cancer. Endocr Relat Cancer (2002) 1.71
New onset hypertension after extracorporeal shock wave lithotripsy: age related incidence and prediction by intrarenal resistive index. J Urol (1997) 1.70
Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res (1995) 1.63
Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS (2001) 1.63
Neobladder emptying failure in males: incidence, etiology and therapeutic options. J Urol (2006) 1.61
Translational regulation via iron-responsive elements by the nitric oxide/NO-synthase pathway. EMBO J (1993) 1.61
Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J Clin Oncol (1998) 1.61
Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem (1989) 1.59
Urethra-sparing cystectomy and orthotopic urinary diversion in women with malignant pelvic tumors. Cancer (2001) 1.58
Rapid signalling by androgen receptor in prostate cancer cells. Oncogene (1999) 1.54
Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr (1999) 1.53
Testicular torsion: late results with special regard to fertility and endocrine function. J Urol (1980) 1.52
Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors. J Pathol (1997) 1.52
vpr deletion mutant of simian immunodeficiency virus induces AIDS in rhesus monkeys. J Virol (1995) 1.51
An evaluation of low-cost progression markers in HIV-1 seropositive Zambians. HIV Med (2000) 1.51
Sildenafil modulates hemodynamics and pulmonary gas exchange. Am J Respir Crit Care Med (2001) 1.50
Neopterin as a new biochemical marker for diagnosis of allograft rejection. Experience based upon evaluation of 100 consecutive cases. Transplantation (1983) 1.47
Laparoscopic surgery for pheochromocytoma: adrenalectomy, partial resection, excision of paragangliomas. J Urol (1998) 1.47
Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status. Br J Haematol (1997) 1.46
Genes differentially expressed in prostate cancer. BJU Int (2004) 1.45
Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer (2002) 1.44
Zoledronic acid influences growth, migration and invasive activity of prostate cancer cells in vitro. Prostate Cancer Prostatic Dis (2012) 1.43
The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene (2006) 1.42
Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sci (1987) 1.42
Antifungal properties of selective serotonin reuptake inhibitors against Aspergillus species in vitro. J Antimicrob Chemother (2001) 1.42
Regulation of prostatic growth and function by peptide growth factors. Prostate (1996) 1.42
Reducing HIV transmission by seronegative blood. Lancet (1992) 1.41
Evaluation of the adaptive learning environments model. Except Child (1988) 1.40
Altered iron metabolism and the anemia of chronic disease: a role of immune activation. Blood (1992) 1.39
Lich-Gregoir reimplantation causes less discomfort than Politano-Leadbetter technique: Results of a prospective, randomized, pain scale-oriented study in a pediatric population. Eur Urol (2005) 1.39
Pteridine biosynthesis in human endothelial cells. Impact on nitric oxide-mediated formation of cyclic GMP. J Biol Chem (1993) 1.35
Pteridines as a new marker to detect human T cells activated by allogeneic or modified self major histocompatibility complex (MHC) determinants. J Immunol (1983) 1.34
Extracorporeal shock wave lithotripsy versus ureteroscopy for distal ureteral calculi: a prospective randomized study. J Urol (1999) 1.33
Efficient class I major histocompatibility complex down-regulation by simian immunodeficiency virus Nef is associated with a strong selective advantage in infected rhesus macaques. J Virol (2001) 1.33
Potential role of immune system activation-associated production of neopterin derivatives in humans. Inflamm Res (2003) 1.32
Parallel induction of tetrahydrobiopterin biosynthesis and indoleamine 2,3-dioxygenase activity in human cells and cell lines by interferon-gamma. Biochem J (1989) 1.31
Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem (2003) 1.31
Effects of systematic formative evaluation: a meta-analysis. Except Child (1986) 1.29
Antifungal activity against Candida species of the selective serotonin-reuptake inhibitor, sertraline. Clin Infect Dis (2001) 1.29
Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus. J Gen Virol (1996) 1.27
The human immunodeficiency virus type 1 nef gene can to a large extent replace simian immunodeficiency virus nef in vivo. J Virol (1999) 1.26
Androgen receptor--an update of mechanisms of action in prostate cancer. Urol Res (2000) 1.25
Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer. Urology (2001) 1.24
The female urethral sphincter: a morphological and topographical study. J Urol (1998) 1.24
Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular carcinoma: long-term outcome. J Urol (2000) 1.24
Radical prostatectomy: the value of preoperative, individually labeled apical biopsies. J Urol (2000) 1.23
Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther (2000) 1.21
Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol (1999) 1.20
Construction, replication, and immunogenic properties of a simian immunodeficiency virus expressing interleukin-2. J Virol (1997) 1.20